Treatment of diabetes mellitus using an external insulin pump: the state of the art.
The aim of diabetes treatment is to achieve tight glucose control to avoid the development of chronic diabetic complications while reducing the frequency of hypoglycaemic episodes. Continuous subcutaneous insulin infusion (CSII) using an external pump is an intensive diabetes therapy recognized to improve metabolic control and glycaemic instability, and to reduce the frequency of severe hypoglycaemia. For years, the theoretical advantages of the insulin pump (constancy of basal delivery, adjustable basal rates, and low insulin depots allowing the reduction of glycaemic variability) have contributed to its reported superiority compared with multiple daily injections (MDI). However, insulin pump therapy is now challenged by new MDI regimens based on long-acting insulin analogues that could replace the use of CSII. As a consequence, health professionals now have to determine which patients are likely to benefit the most from CSII. Recently, several studies reported that children and adolescents, and patients whose blood glucose imbalance was initially the most pronounced with basal-bolus regimens, would particularly benefit from CSII. Other indications were also proposed in marginal clinical situations with highly selected patients in whom a significant improvement of blood glucose was demonstrated. Finally, the use of CSII in type 2 diabetic patients now appears to be a good alternative to the ineffective MDI regimens observed in some of these patients. However, past experience with CSII indicates that candidates for insulin pump therapy must be carefully selected and strongly motivated to improve their glucose control. Use of CSII also requires strict medical supervision by physicians and a regular programme of patient education by paramedical teams, to ensure optimal responsible use of this technique by healthcare professionals.
Hanaire
H
H
Hôpital de Rangueil, CHU de Toulouse, 1 avenue Professeur Jean-Poulhes, Toulouse Cedex, France.
Lassmann-Vague
V
V
Jeandidier
N
N
Renard
E
E
Tubiana-Rufi
N
N
Vambergue
A
A
Raccah
D
D
Pinget
M
M
Guerci
B
B
D003920:Diabetes Mellitus / Q000188:drug therapy*; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy*; D004867:Equipment Design; D007328:Insulin / Q000627:therapeutic use; D007332:Insulin Infusion Systems / Q000009:adverse effects / Q000639:trends*; D061389:Insulin, Regular, Pork
D007328:Insulin; D061389:Insulin, Regular, Pork; C000006:insulin, neutral